News
NRXS
6.24
+3.23%
0.20
Weekly Report: what happened at NRXS last week (0720-0724)?
Weekly Report · 3d ago
Neuraxis files to sell 1.92M shares of common stock for holders
TipRanks · 6d ago
Fourteen new option listings and one option delisting on July 22nd
TipRanks · 07/22 12:30
Weekly Report: what happened at NRXS last week (0713-0717)?
Weekly Report · 07/20 10:05
Weekly Report: what happened at NRXS last week (0706-0710)?
Weekly Report · 07/13 10:06
NeurAxis Declares Q2 Stock Dividend on Series B
TipRanks · 07/10 11:27
Weekly Report: what happened at NRXS last week (0629-0703)?
Weekly Report · 07/06 10:10
Weekly Report: what happened at NRXS last week (0622-0626)?
Weekly Report · 06/29 10:05
Weekly Report: what happened at NRXS last week (0615-0619)?
Weekly Report · 06/22 10:13
Weekly Report: what happened at NRXS last week (0608-0612)?
Weekly Report · 06/15 10:14
NeurAxis Stockholders Approve Directors and Equity Compensation Plans
TipRanks · 06/12 23:28
Weekly Report: what happened at NRXS last week (0601-0605)?
Weekly Report · 06/08 10:10
Weekly Report: what happened at NRXS last week (0525-0529)?
Weekly Report · 06/01 10:14
Weekly Report: what happened at NRXS last week (0518-0522)?
Weekly Report · 05/25 10:17
NeurAxis Earnings Call Highlights Growth and Hurdles
TipRanks · 05/20 08:34
Weekly Report: what happened at NRXS last week (0511-0515)?
Weekly Report · 05/18 10:17
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y
NASDAQ · 05/15 16:23
NeurAxis signals burn rate of $1M or less for rest of 2026 while targeting ~ $15M revenue for cash flow breakeven
Seeking Alpha · 05/12 20:42
Craig-Hallum Sticks to Its Buy Rating for NeurAxis, Inc. (NRXS)
TipRanks · 05/12 20:37
NeurAxis reports Q1 results
Seeking Alpha · 05/12 16:57
More
Webull provides a variety of real-time NRXS stock news. You can receive the latest news about Neuraxis Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXS
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension.